Construction and in Vitro Evaluation of a Novel Anti-CD25 Chimeric Antigen Recepto

The interleukin-2 (IL-2) receptor has been an attractive target to treat hematologic malignancies for decades, in as much as CD25 is expressed on lymphoma or leukemia cells of T- and B-cell origin, including Adult T-cell leukemia/lymphoma, chronic lymphocytic leukemia, cutaneous T-cell lymphoma (CTCL), Hodgkin's disease, as well as B-cell non-Hodgkin's lymphoma. To date, there are no FDA approved chimeric antigen receptor T-cells (CAR-T) that treat T-cell neoplasms, so an effective CAR-T that targets a T-cell neoplasm such as Adult T-cell leukemia/lymphoma, is direly needed.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 225 Source Type: research